[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100271319":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":32,"locations":39,"responsibleParty":59,"collaborators":25,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"THC","ACTIVE_COMPARATOR","10 mg Dronabinol will be administered orally.",[13],"Drug: Dronabinol",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo pill (no active cannabinoids).",[19],"Drug: Placebo",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Placebo pill (no active cannabinoids)",[15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Dronabinol","10 mg capsule of Dronabinol will be administered orally.",[9],[31],"Delta-9-Tetrahydrocannabinol",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Carly Hewes, BS","CONTACT","(203)932-5711","7411","carly.hewes@yale.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine","RECRUITING","West Haven","Connecticut","06516","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-72.94705,41.27065,{"lat":52,"lon":51},[55,56],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},{"name":57,"role":58,"phone":25,"phoneExt":25,"email":25},"Mohini Ranganathan, MD","PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mohini Ranganathan","Assistant Professor of Psychiatry","100271319","phase-1-gender-related-differences-in-the-acute-effects-of-delta-9-tetrahydrocannabinol-in-healthy-humans-sub-study-i-100271319",false,"NCT02811510","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I","THC-Gender-I","Inclusion Criteria:\n\n* At least one lifetime exposure to cannabis\n* Good physical and mental health\n\nExclusion Criteria:\n\n* Cannabis naive individuals\n* Major current or recent stressors\n* Taking estrogen supplements or oral contraceptive pills (for women)\n* Sesame oil allergy",true,"ALL","18 Years","55 Years",{"count":74,"type":75},40,"ESTIMATED","INTERVENTIONAL",[78],"PHASE1","The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.",[81],"Cannabis","2025-06-05",{"date":84,"type":85},"2025-06-10","ACTUAL",{"date":87,"type":25},"2016-06",{"date":89,"type":75},"2026-12",{"name":5,"class":6},1]